Skip to main content

Publications

What type of publication do you want to show?

2024

2023

<i>DPYD</i>genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: A systematic review

DOI
10.1101/2023.12.11.23299813
Preprint

Characterization of Drug-Specific CD4+T-Cells Reveals Possible Roles of HLA Class II in the Pathogenesis of Carbamazepine Hypersensitivity Reactions

Jaruthamsophon, K., Thomson, P. J., Hammond, S., Zhang, E., Alfirevic, A., Sukasem, C., . . . Pirmohamed, M. (2023). Characterization of Drug-Specific CD4+T-Cells Reveals Possible Roles of HLA Class II in the Pathogenesis of Carbamazepine Hypersensitivity Reactions. CHEMICAL RESEARCH IN TOXICOLOGY. doi:10.1021/acs.chemrestox.2c00414

DOI
10.1021/acs.chemrestox.2c00414
Journal article

Developing a warfarin dosing algorithm in patients with mechanical heart valves

Zhang, E., Stewart, A., Jorgensen, A., McEvoy, L., Carracedo, A. D., Foster, T., . . . Pirmohamed, M. (2023). Developing a warfarin dosing algorithm in patients with mechanical heart valves. In BRITISH JOURNAL OF CLINICAL PHARMACOLOGY Vol. 89 (pp. 1249-1250). Retrieved from https://www.webofscience.com/

Conference Paper

2022

A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients.

Asiimwe, I. G., Blockman, M., Cohen, K., Cupido, C., Hutchinson, C., Jacobson, B., . . . Pirmohamed, M. (2022). A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients.. Frontiers in pharmacology, 13, 967082. doi:10.3389/fphar.2022.967082

DOI
10.3389/fphar.2022.967082
Journal article

Stable warfarin dose prediction in sub-Saharan African patients: A machine-learning approach and external validation of a clinical dose-initiation algorithm

Asiimwe, I. G., Blockman, M., Cohen, K., Cupido, C., Hutchinson, C., Jacobson, B., . . . Pirmohamed, M. (2022). Stable warfarin dose prediction in sub-Saharan African patients: A machine-learning approach and external validation of a clinical dose-initiation algorithm. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 11(1), 20-29. doi:10.1002/psp4.12740

DOI
10.1002/psp4.12740
Journal article

2021

Systems analysis of miRNA biomarkers to inform drug safety

Schofield, A. L., Brown, J. P., Brown, J., Wilczynska, A., Bell, C., Glaab, W. E., . . . Goldring, C. (2021). Systems analysis of miRNA biomarkers to inform drug safety. ARCHIVES OF TOXICOLOGY, 95(11), 3475-3495. doi:10.1007/s00204-021-03150-9

DOI
10.1007/s00204-021-03150-9
Journal article

Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort

Yates, T., Zaccardi, F., Islam, N., Razieh, C., Gillies, C. L., Lawson, C. A., . . . Khunti, K. (2021). Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort. OBESITY, 29(7), 1223-1230. doi:10.1002/oby.23178

DOI
10.1002/oby.23178
Journal article

Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study

Gupta, R. K., Harrison, E. M., Ho, A., Docherty, A. B., Knight, S. R., van Smeden, M., . . . Noursadeghi, M. (2021). Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. LANCET RESPIRATORY MEDICINE, 9(4), 349-359. doi:10.1016/S2213-2600(20)30559-2

DOI
10.1016/S2213-2600(20)30559-2
Journal article

Warfarin dosing algorithms: A systematic review

Asiimwe, I. G., Zhang, E. J., Osanlou, R., Jorgensen, A. L., & Pirmohamed, M. (2021). Warfarin dosing algorithms: A systematic review. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(4), 1717-1729. doi:10.1111/bcp.14608

DOI
10.1111/bcp.14608
Journal article

2020

Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020

Thompson, C. P., Grayson, N. E., Paton, R. S., Bolton, J. S., Lourenco, J., Penman, B. S., . . . Simmonds, P. (2020). Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. EUROSURVEILLANCE, 25(42), 33-41. doi:10.2807/1560-7917.ES.2020.25.42.2000685

DOI
10.2807/1560-7917.ES.2020.25.42.2000685
Journal article

2019

Genomewide Association Study of Statin‐Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink

Carr, D. (2019). Genomewide Association Study of Statin‐Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink. Clinical Pharmacology and Therapeutics, 106(6), 1353-1361. doi:10.1002/cpt.1557

DOI
10.1002/cpt.1557
Journal article

2018

2017

2016

Investigating the role of microRNA on warfarin response

Zhang, J. E. (n.d.). Investigating the role of microRNA on warfarin response. In Pharmacology 2015. London.

Conference Paper

2015

Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry

Alfirevic, A., Durocher, J., Elati, A., Leon, W., Dickens, D., Raedisch, S., . . . Winikoff, B. (2015). Misoprostol-induced fever and genetic polymorphisms in drug transporters <i>SLCO1B1</i> and <i>ABCC4</i> in women of Latin American and European ancestry. PHARMACOGENOMICS, 16(9), 919-928. doi:10.2217/pgs.15.53

DOI
10.2217/pgs.15.53
Journal article

2014

Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.

Hawcutt, D., Ghani, A., Sutton, L., Jorgensen, A., Zhang, E., Murray, M., . . . Pirmohamed, M. (2014). Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects.. The Pharmacogenomics Journal, 14(6), 542-548. doi:10.1038/tpj.2014.31

DOI
10.1038/tpj.2014.31
Journal article

Dual Glutathione-<i>S</i>-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia

Davies, A., Giannoudis, A., Zhang, J. E., Austin, G., Wang, L., Holyoake, T. L., . . . Clark, R. E. (2014). Dual Glutathione-<i>S</i>-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia. CLINICAL PHARMACOLOGY & THERAPEUTICS, 96(6), 694-703. doi:10.1038/clpt.2014.176

DOI
10.1038/clpt.2014.176
Journal article

Is the Interleukin 8 Promoter Polymorphism rs4073/–251T >A Associated With Clostridium difficile Infection?

Miyajima, F., Swale, A., Zhang, E., Alfirevic, A., Little, M., Beeching, N., . . . Pirmohamed, M. (2014). Is the Interleukin 8 Promoter Polymorphism rs4073/–251T >A Associated With Clostridium difficile Infection?. Clinical Infectious Disease, 58(12), e148-e151. doi:10.1093/cid/ciu152

DOI
10.1093/cid/ciu152
Journal article

2013

A Randomized Trial of Genotype-Guided Dosing of Warfarin

Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., . . . Wadelius, M. (2013). A Randomized Trial of Genotype-Guided Dosing of Warfarin. NEW ENGLAND JOURNAL OF MEDICINE, 369(24), 2294-2303. doi:10.1056/NEJMoa1311386

DOI
10.1056/NEJMoa1311386
Journal article

A Randomized Trial of Genotype-Guided Dosing of Warfarin

Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., . . . Wadelius, M. (2013). A Randomized Trial of Genotype-Guided Dosing of Warfarin. New England Journal of Medicine, 369(24), 2294-2303. doi:10.1056/nejmoa1311386

DOI
10.1056/nejmoa1311386
Journal article

<i>CYP2C19*17</i> Gain-of-Function Polymorphism Is Associated With Peptic Ulcer Disease

Musumba, C. O., Jorgensen, A., Sutton, L., Van Eker, D., Zhang, E., O'Hara, N., . . . Pirmohamed, M. (2013). <i>CYP2C19*17</i> Gain-of-Function Polymorphism Is Associated With Peptic Ulcer Disease. CLINICAL PHARMACOLOGY & THERAPEUTICS, 93(2), 195-203. doi:10.1038/clpt.2012.215

DOI
10.1038/clpt.2012.215
Journal article

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia

Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. BLOOD, 121(4), 628-637. doi:10.1182/blood-2012-01-405035

DOI
10.1182/blood-2012-01-405035
Journal article

The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia

Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia. Blood, 121, 628-637.

Journal article

2012

Impact of the <i>CYP4F2</i> p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis

Danese, E., Montagnana, M., Johnson, J. A., Rettie, A. E., Zambon, C. F., Lubitz, S. A., . . . Fava, C. (2012). Impact of the <i>CYP4F2</i> p.V433M Polymorphism on Coumarin Dose Requirement: Systematic Review and Meta-Analysis. CLINICAL PHARMACOLOGY & THERAPEUTICS, 92(6), 746-756. doi:10.1038/clpt.2012.184

DOI
10.1038/clpt.2012.184
Journal article

CYP2C19*17 GAIN OF FUNCTION MUTATION IS ASSOCIATED WITH PEPTIC ULCER DISEASE

Musumba, C. O., Eker, D. V., Jorgensen, A., Pritchard, D. M., & Pirmohamed, M. (2012). CYP2C19*17 GAIN OF FUNCTION MUTATION IS ASSOCIATED WITH PEPTIC ULCER DISEASE. GUT, 61, A363. doi:10.1136/gutjnl-2012-302514d.165

DOI
10.1136/gutjnl-2012-302514d.165
Journal article

2009

Effects of <i>CYP4F2</i> genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy

Zhang, J. E., Jorgensen, A. L., Alfirevic, A., Williamson, P. R., Toh, C. H., Park, B. K., & Pirmohamed, M. (2009). Effects of <i>CYP4F2</i> genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. PHARMACOGENETICS AND GENOMICS, 19(10), 781-789. doi:10.1097/FPC.0b013e3283311347

DOI
10.1097/FPC.0b013e3283311347
Journal article

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study

Jorgensen, A. L., Al-Zubiedi, S., Zhang, J. E., Keniry, A., Hanson, A., Hughes, D. A., . . . Pirmohamed, M. (2009). Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. PHARMACOGENETICS AND GENOMICS, 19(10), 800-812. doi:10.1097/FPC.0b013e3283317ab5

DOI
10.1097/FPC.0b013e3283317ab5
Journal article

EFFECTS OF CYP4F2 GENETIC POLYMORPHISMS AND HAPLOTYPES ON CLINICAL OUTCOMES IN PATIENTS INITIATED ON WARFARIN THERAPY

Zhang, J. E., Jorgensen, A. L., Alfirevica, A., Williamson, P. R., Toh, C. H., Park, B. K., & Pirmohamed, M. (2009). EFFECTS OF CYP4F2 GENETIC POLYMORPHISMS AND HAPLOTYPES ON CLINICAL OUTCOMES IN PATIENTS INITIATED ON WARFARIN THERAPY. Pharmacogenetics and Genomics, (19), 781-789.

Journal article